Farouk SS , Rein JL . The many faces of calcineurin inhibitor toxicity—What the FK? Adv Chronic Kidney Dis 2020; 27:56–66. doi: 10.1053/j.ackd.2019.08.006
Vincenti F , et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016; 374:333–343. doi: 10.1056/NEJMoa1506027. Erratum in: N Engl J Med 2016; 374:698. doi: 10.1056/NEJMx160003
Adams AB , et al. Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant 2017; 17:2922–2936. doi: 10.1111/ajt.14353
Cicora F , et al. Belatacept-based, ATG-Fresenius-induction regimen for kidney transplant recipients: A proof-of-concept study. Transpl Immunol 2015; 32:35–39. doi: 10.1016/j.trim.2014.10.002
Kumar D , et al. Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants. Front Med (Lausanne) 2017; 4:60. doi: 10.3389/fmed.2017.00060
Ferguson R , et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11:66–76. doi: 10.1111/j.1600-6143.2010.03338.x
Radbruch A , et al. Competence and competition: The challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6:741–750. doi: 10.1038/nri1886
Ajaz B , et al. Plasma cell CD20 expression: Primary aberrant expression or receptor up-regulation. Leuk Lymphoma 2014; 55:444−446. doi: 10.3109/10428194.2013.802782
Lee J , et al. The effect of bortezomib on antibody-mediated rejection after kidney transplantation. Yonsei Med J 2015; 56:1638–1642. doi: 10.3349/ymj.2015.56.6.1638
Woodle ES , et al. Plasma cell targeting to prevent antibody-mediated rejection. Am J Transplant 2020; 20:33–41. doi: 10.1111/ajt.15889